专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008074413A2 HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS 审中-公开
标题翻译：异丙烯酰胺和它们作为药物的用途
公开(公告)号：WO2008074413A2
公开(公告)日：2008-06-26
申请号：PCT/EP2007010709
申请日：2007-12-08
申请人： SANOFI AVENTIS , STROBEL HARTMUT , WOHLFART PAULUS , KLEEMANN HEINZ-WERNER , ZOLLER GERHARD , WILL DAVID WILLIAM
发明人： STROBEL HARTMUT , WOHLFART PAULUS , KLEEMANN HEINZ-WERNER , ZOLLER GERHARD , WILL DAVID WILLIAM
IPC分类号： C07D213/50 , A61K31/4523 , A61P9/00 , C07D401/06 , C07D407/06 , C07D409/06 , C07D409/14 , C07D413/06 , C07D417/06
CPC分类号： C07D213/56 , C07D213/64 , C07D213/73 , C07D213/75 , C07D215/12 , C07D233/64 , C07D233/68 , C07D239/26 , C07D277/30 , C07D277/46 , C07D333/24 , C07D333/60 , C07D401/06 , C07D401/12 , C07D405/12 , C07D409/04 , C07D409/06 , C07D409/12 , C07D413/06 , C07D417/06 , C07D417/12
摘要： The present invention relates to heteroarylacrylamides of the formula (I), in which Het, X, R a , R b , R 1 , R 2 and R 3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula (I) upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of the formula (I), to pharmaceutical compositions comprising them, and to the use of compounds of the formula I for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.
摘要翻译：本发明涉及式（I）的杂芳基丙烯酰胺，其中Het，X，R a，R b，R i，R i，R b， R 2和R 3具有权利要求书中所示的含义，其调节内皮一氧化氮（NO）合酶的转录并且是有价值的药理活性化合物。具体地，式（I）化合物上调酶内皮NO合成酶的表达，并且可以在需要增加所述酶的表达或增加的NO水平或降低的NO水平的标准化的条件下使用。本发明还涉及制备式（I）化合物，包含它们的药物组合物的方法，以及式I化合物在制备用于刺激内皮NO合成酶表达的药物中的用途或用于治疗包括心血管疾病如动脉粥样硬化，血栓形成，冠状动脉疾病，高血压和心功能不全等各种疾病。

2. 发明申请

WO2008104278A8 IMIDAZO[1,2-A] PYRIDINES AND THEIR USE AS PHARMACEUTICALS 审中-公开
标题翻译：咪唑并[1,2-A]吡啶并用作药物
公开(公告)号：WO2008104278A8
公开(公告)日：2009-01-29
申请号：PCT/EP2008001150
申请日：2008-02-15
申请人： SANOFI AVENTIS , ZOLLER GERHARD , STROBEL HARTMUT , WILL DAVID WILLIAM , WOHLFART PAULUS
发明人： ZOLLER GERHARD , STROBEL HARTMUT , WILL DAVID WILLIAM , WOHLFART PAULUS
IPC分类号： A61K31/437 , A61P9/02 , A61P9/08 , A61P11/00 , A61P19/10 , C07D401/04
CPC分类号： C07D471/04
摘要： The present invention relates to derivatives of imidazo[1,2-a]pyridines of the formula (I), in which R, R1 to R4 and n have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula (I) upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of the formula (I), to pharmaceutical compositions comprising them, and to the use of compounds of the formula (I) for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.
摘要翻译：本发明涉及式（I）的咪唑并[1,2-a]吡啶衍生物，其中R，R 1至R 4和n具有权利要求中所示的含义，其调节内皮一氧化氮（NO ）合成酶，是有价值的药理活性化合物。具体地，式（I）化合物上调酶内皮NO合成酶的表达，并且可以在需要增加所述酶的表达或增加的NO水平或降低的NO水平的标准化的条件下使用。本发明还涉及制备式（I）化合物，包含它们的药物组合物的方法，以及式（I）化合物在制备用于刺激内皮细胞表达的药物中的应用 NO合成酶或用于治疗包括心血管疾病如动脉粥样硬化，血栓形成，冠状动脉疾病，高血压和心脏功能不全等各种疾病。

3. 发明专利

JP2010100622A Acylated indanyl amine and use thereof as pharmaceutical 有权
标题翻译：丙酸胺和其作为药物的用途
公开(公告)号：JP2010100622A
公开(公告)日：2010-05-06
申请号：JP2009244620
申请日：2009-10-23
申请人： Sanofi-Aventis Deutschland Gmbh , サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
发明人： STROBEL HARTMUT , WOHLFART PAULUS , SAFAROVA ALENA , WALSER ARMIN , SUZUKI TERI , DHARANIPRAGADA RAMALINGA M , SCHOENAFINGER KARL
IPC分类号： C07C233/04 , C07C233/65 , A61K9/02 , A61K9/06 , A61K9/08 , A61K9/10 , A61K9/107 , A61K9/12 , A61K9/16 , A61K9/20 , A61K9/28 , A61K9/30 , A61K9/36 , A61K9/48 , A61K9/50 , A61K9/72 , A61K31/165 , A61K31/166 , A61K31/18 , A61K31/194 , A61K31/222 , A61K31/341 , A61K31/343 , A61K31/357 , A61K31/36 , A61K31/38 , A61K31/381 , A61K31/40 , A61K31/404 , A61K31/405 , A61K31/415 , A61K31/416 , A61K31/4172 , A61K31/4184 , A61K31/4192 , A61K31/42 , A61K31/4245 , A61K31/427 , A61K31/433 , A61K31/435 , A61K31/4365 , A61K31/437 , A61K31/44 , A61K31/4406 , A61K31/4409 , A61K31/4425 , A61K31/4439 , A61K31/455 , A61K31/47 , A61K31/473 , A61K31/4965 , A61K31/497 , A61K31/498 , A61K31/501 , A61K31/502 , A61K31/505 , A61K31/538 , A61K31/5513 , A61P1/16 , A61P3/10 , A61P7/02 , A61P9/00 , A61P9/04 , A61P9/06 , A61P9/10 , A61P9/12 , A61P11/00 , A61P11/06 , A61P13/12 , A61P15/10 , A61P19/10 , A61P25/28 , A61P43/00 , C07C233/58 , C07C233/64 , C07C233/66 , C07C233/67 , C07C233/74 , C07C233/76 , C07C235/42 , C07C235/44 , C07C235/54 , C07C235/82 , C07C235/84 , C07C237/28 , C07C237/30 , C07C237/38 , C07C237/42 , C07C237/52 , C07C255/57 , C07C255/60 , C07C309/04 , C07C309/66 , C07C309/73 , C07C311/08 , C07C311/16 , C07C311/21 , C07C311/42 , C07C317/44 , C07C323/42 , C07C323/56 , C07C323/62 , C07D207/325 , C07D207/327 , C07D207/34 , C07D209/08 , C07D209/42 , C07D213/56 , C07D213/81 , C07D213/82 , C07D215/48 , C07D215/52 , C07D219/04 , C07D231/14 , C07D231/56 , C07D233/90 , C07D235/08 , C07D237/28 , C07D239/26 , C07D239/42 , C07D241/24 , C07D241/44 , C07D243/14 , C07D249/04 , C07D249/06 , C07D249/18 , C07D261/18 , C07D265/36 , C07D271/08 , C07D277/20 , C07D277/56 , C07D285/06 , C07D295/12 , C07D295/185 , C07D307/68 , C07D307/78 , C07D307/79 , C07D307/84 , C07D307/85 , C07D317/60 , C07D317/68 , C07D319/16 , C07D319/18 , C07D333/24 , C07D333/38 , C07D333/40 , C07D333/68 , C07D333/70 , C07D401/06 , C07D403/04 , C07D405/04 , C07D471/04 , C07D495/04
CPC分类号： C07D213/81 , C07C233/58 , C07C233/65 , C07C233/66 , C07C233/74 , C07C233/76 , C07C235/42 , C07C235/54 , C07C235/84 , C07C237/38 , C07C237/42 , C07C255/57 , C07C255/60 , C07C309/66 , C07C309/73 , C07C311/08 , C07C311/16 , C07C311/21 , C07C317/44 , C07C323/62 , C07C2601/02 , C07C2601/08 , C07C2602/08 , C07D207/34 , C07D213/56 , C07D213/82 , C07D215/48 , C07D235/08 , C07D241/24 , C07D249/04 , C07D261/18 , C07D295/185 , C07D307/78 , C07D307/84 , C07D317/60 , C07D333/24 , C07D401/06
摘要： PROBLEM TO BE SOLVED: To provide a compound that upregulates manifestation of endothelial NO-synthase. SOLUTION: There are provided acylated indanyl amines represented by general formula (I) [wherein R 1 to R 4 are each independently selected from the group consisting of H, an unsubstituted or substituted 1-16C alkyl at one or more positions and the like; A is selected from the group consisting of CH 2 , CHOH and a CH-(1-3C alkyl); B is selected from the group consisting of CH 2 and a CH-(1-3C alkyl); and R 5 indicates an aryl group or a heteroaryl group], its pharmaceutically acceptable salt and the like and a pharmaceutical preparation containing these for curing particularly cardiovascular disorder. COPYRIGHT: (C)2010,JPO&INPIT
摘要翻译：待解决的问题：提供上调内皮NO合成酶表现的化合物。提供由通式（I）表示的酰化茚满胺[其中R 1和R 4彼此独立地选自H，一个或多个位置的未取代或取代的1-16C烷基等; A选自CH 2 SB，CHOH和CH-（1-3C烷基）; B选自CH 2 SB 2和CH-（1-3C烷基）; R＆lt; SP＆gt; 5＆lt; SP＆gt;表示芳基或杂芳基]，其药学上可接受的盐等，以及含有这些用于治疗特别是心血管疾病的药物。版权所有（C）2010，JPO＆INPIT

5. 发明专利

AU2004232456B2 Triaza- and tetraaza-anthracenedione derivatives, their preparation and their use as pharmaceuticals 未知
公开(公告)号：AU2004232456B2
公开(公告)日：2010-06-17
申请号：AU2004232456
申请日：2004-04-13
申请人： SANOFI AVENTIS DEUTSCHLAND
发明人： WOHLFART PAULUS , SMRCINA MARTIN , STROBEL HARTMUT , PATEK MARCEL , WEICHERT ANDREAS , WEICHSEL ALEKSANDRA
IPC分类号： C07D471/14 , A61P9/00 , C07D487/04
摘要： A triaza- and tetraaza-anthracenedione derivatives, its stereoisomeric forms or mixture, or salts are new. A triaza- and tetraaza-anthracenedione derivatives of formula (I), its stereoisomeric forms or mixture, or salts are new. [Image] A : CR 6 or N; B : CR 7 or N; R 11-10C alkyl, 3-8C cycloalkyl, 2-10C alkenyl or 2-10C alkynyl (all optionally substituted by halo, CN, 3-8C cycloalkyl, phenyl, biphenylyl, naphthyl, indanyl or heteroaryl); R 2H, 1-4C alkyl, CF 3, -(CH 2) a-3-8C cycloalkyl, -(CH 2) a-phenyl, -(CH 2) a-imidazolyl or -(CH 2) a-pyridinyl; a : 0 - 2; R 3-(CH 2) b-phenyl, -(CH 2) b-imidazolyl, -(CH-2) b-triazolyl, -(CH 2) b-Het or -(CH 2) b-pyridinyl; b : 1 - 4; R 4 - R 7H, 1-4C alkyl, CF 3, 1-4C alkoxy, OCF 3, halo, nitro, CN, -CO-R 1 0, -NR 8R 9, -NH-CO-1-4C alkyl, -SO 2-NR 8R 9, -SO 2-1-4C alkyl or -SO 2-(CH 2) c-phenyl; c : 0 - 2; R 8 and R 9H or 1-4C alkyl; R 1 0OH, 1-4C alkoxy or -NR 8R 9; Het : a residue of a saturated 5- or 6-membered monocyclic heterocycle (contains a ring nitrogen via which it is bonded, and additionally contains a further ring heteroatom selected from N, O and S, and optionally substituted by 1-4C alkyl or -(CH 2) d-phenyl); d : 0 - 2; Heteroaryl : a residue of an aromatic 5 - 10 membered, monocyclic or bicyclic heterocycle (contains 1 - 4 N, O and S). The residues phenyl, biphenylyl, naphthyl, indanyl, heteroaryl, pyridinyl, imidazolyl and triazolyl are optionally substituted by halo, CN, 1-6C alkyl, CF 3, 1-6C alkoxy or OCF 3. A and B are not simultaneously N. An independent claim is included for preparation of (I). ACTIVITY : Cardiovascular-Gen.; Antianginal; Cardiant; Cerebroprotective; Vasotropic; Thrombolytic; Antiarteriosclerotic; Hypotensive; Respiratory-Gen.; Nephrotropic; Antiarrhythmic; Antidiabetic; Ophthalmological; Antiasthmatic; Antiangiogenic; Hepatotropic; Osteopathic. MECHANISM OF ACTION : Endothelial nitric oxide (NO) synthase (eNOS) expression stimulator. (4S)-9-(3-(Imidazo)-1-yl)propyl)-4-isopropyl-6-nitro-2-(4-phenylbutyl)-1,2,9,9a-tetrahydro-2,4a,9-triaza-anthracene- 3,10(4H)-dione trifluoroacetic acid (Ia) was tested for activation of eNOS transcription as described in Li et al., Activation of protein kinase C alpha and/or epsilon enhances transcription of the human endothelial nitric oxide synthase gene, Mol. Pharmacol. 53 (1998) 630. (Ia) Showed an EC 5 0 of 2.2 mM.

6. 发明专利

CA2745240A1 METHODS AND USES INVOLVING HEME BINDING PROTEIN 1 未知
公开(公告)号：CA2745240A1
公开(公告)日：2010-06-10
申请号：CA2745240
申请日：2009-11-27
申请人： SANOFI AVENTIS
发明人： KRUG ALEXANDRA , KRUIP JOCHEN , WOHLFART PAULUS , GASSENHUBER JOHANN , HEERMEIER KATHRIN , STROBEL HARTMUT , KARST NATALIE , FERRIER ALEXANDRA , VISKOV CHRISTIAN
IPC分类号： G01N33/68 , A61K38/00
摘要： The present invention relates to a method of screening for a modulator of endothelial NO synthase (eNOS) expression, a method of diagnosing a cardiovascular disease in a subject, the use of HEBP-1 for the identification of a medicament for preventing and/or treating a disease involving eNOS dysfunction, particularly a cardiovascular disease, the use of HEBP-1 for the detection of a component of eNOS signal transduction, and the use of HEBP1 for the regulation of eNOS promoter activity.

7. 发明专利

ES2322964T3 AMIDAS SUSTITUIDAS CON HETEROARILO QUE COMPRENDEN UN GRUPO DE UNION INSATURADO O CICLICO, Y SU USO COMO AGENTES FARMACEUTICOS. 未知
公开(公告)号：ES2322964T3
公开(公告)日：2009-07-02
申请号：ES06754359
申请日：2006-06-14
申请人： SANOFI AVENTIS
发明人： STROBEL HARTMUT , WOHLFART PAULUS , ZOLLER GERHARD , WILL DAVID WILLIAM
IPC分类号： C07D401/06 , A61K31/4439 , A61K31/444 , A61P9/08 , C07D401/08 , C07D401/14 , C07D409/14 , C07D417/06
摘要： Un compuesto de la fórmula I, **(Ver fórmula)** en la que A se selecciona entre -CH=CH-CH2-, -C C-CH2-, en la que los grupos están unidos al grupo Het vía el átomo terminal del doble o triple enlace, al grupo de la fórmula II, que está unido al grupo Het vía un átomo de anillo y al grupo de la fórmula III, **(Ver fórmula)** en la que en las fórmulas II y III los enlaces vía los cuales se conectan los grupos a los grupos adyacentes, se representan mediante las líneas que comienzan en los átomos de anillo y en el grupo (CH2)r , y en la que todos los grupos A pueden estar sustituidos con uno o más sustituyentes R 4 idénticos o diferentes; Het es un grupo aromático, monocíclico, de 5 miembros o de 6 miembros que contiene uno o dos miembros hetero en el anillo iguales o diferentes elegidos entre N, NR 13 , O y S y que pueden estar sustituidos con uno o más sustituyentes R 5 iguales o diferentes; X se elige entre un enlace directo, CH2, O y NH; R 1 y R 2 se eligen independientemente entre sí entre alquilo (C1-C6), alquenilo (C3-C6), alquinilo (C3-C6), cicloalquil (C3-C7)-CnH2n-, fenil-CnH2n- y heteroaril-CnH2n-, y R 2 puede ser además hidrógeno, donde los grupos alquilo (C1-C6), cicloalquilo (C3-C7), alquenilo (C3-C6) y alquinilo (C3-C6) pueden estar todos sustituidos con uno o más sustituyentes R 6 iguales o diferentes, y los grupos CnH2n pueden estar todos sustituidos con uno o más sustituyentes iguales o diferentes elegidos entre flúor y alquilo (C1-C4), y todos los grupos fenilo y grupos heteroarilo pueden estar sustituidos independientemente entre sí con uno o más sustituyentes R 7 iguales o diferentes, o R 1 y R 2 , junto con el grupo N-CO que los tiene, forman un anillo monocíclico o bicíclico, saturado o insaturado, de 4 miembros a 10 miembros, que, además del átomo de nitrógeno del anillo que forma parte del grupo N-CO, puede contener uno o dos miembros hetero en el anillo elegidos entre N, NR 12 , O, S, SO y SO2 que pueden ser iguales o diferentes, con la condición de que dos miembros del anillo de la serie O, S, SO y SO2 no puedan estar presentes en posiciones adyacentes del anillo, donde el anillo formado por R 1 y R 2 y el grupo N-CO que los tiene puede estar sustituido con uno o más sustituyentes R 8 iguales o diferentes; ...

9. 发明专利

AU2002253010B8 Acylated indanyl amines and their use as pharmaceuticals 未知
公开(公告)号：AU2002253010B8
公开(公告)日：2009-04-02
申请号：AU2002253010
申请日：2002-02-12
申请人： SANOFI AVENTIS DEUTSCHLAND
发明人： WALSER ARMIN , SAFAROVA ALENA , SCHOENAFINGER KARL , STROBEL HARTMUT , SUZUKI TERI , DHARANIPRAGADA RAMALINGA M , WOHLFART PAULUS
IPC分类号： A61K9/02 , C07C233/04 , A61K9/06 , A61K9/08 , A61K9/10 , A61K9/12 , A61K9/16 , A61K9/28 , A61K9/50 , A61K9/72 , A61K31/165 , A61K31/166 , A61K31/18 , A61K31/194 , A61K31/222 , A61K31/341 , A61K31/343 , A61K31/357 , A61K31/36 , A61K31/38 , A61K31/381 , A61K31/40 , A61K31/404 , A61K31/415 , A61K31/4184 , A61K31/4192 , A61K31/42 , A61K31/4245 , A61K31/427 , A61K31/433 , A61K31/435 , A61K31/4365 , A61K31/437 , A61K31/4409 , A61K31/4425 , A61K31/4439 , A61K31/455 , A61K31/473 , A61K31/4965 , A61K31/498 , A61K31/501 , A61K31/502 , A61K31/505 , A61K31/538 , A61K31/5513 , A61P1/16 , A61P3/10 , A61P7/02 , A61P9/00 , A61P9/06 , A61P9/10 , A61P9/12 , A61P11/06 , A61P13/12 , A61P15/10 , A61P19/10 , A61P25/28 , A61P43/00 , C07C233/58 , C07C233/64 , C07C233/65 , C07C233/66 , C07C233/74 , C07C233/76 , C07C235/42 , C07C235/44 , C07C235/54 , C07C235/84 , C07C237/28 , C07C237/38 , C07C237/42 , C07C255/57 , C07C255/60 , C07C309/66 , C07C309/73 , C07C311/08 , C07C311/16 , C07C311/21 , C07C317/44 , C07C323/56 , C07C323/62 , C07D207/325 , C07D207/34 , C07D209/08 , C07D209/42 , C07D213/56 , C07D213/81 , C07D213/82 , C07D215/48 , C07D215/52 , C07D219/04 , C07D231/14 , C07D233/90 , C07D235/08 , C07D237/28 , C07D239/26 , C07D239/42 , C07D241/24 , C07D241/44 , C07D243/14 , C07D249/04 , C07D249/06 , C07D249/18 , C07D261/18 , C07D265/36 , C07D271/08 , C07D277/20 , C07D277/56 , C07D285/06 , C07D295/12 , C07D295/185 , C07D307/68 , C07D307/78 , C07D307/79 , C07D307/84 , C07D307/85 , C07D317/60 , C07D317/68 , C07D319/18 , C07D333/24 , C07D333/40 , C07D333/70 , C07D401/06 , C07D403/04 , C07D471/04 , C07D495/04
摘要： The present invention relates to acylated indanyl amines according to the general formula (I) wherein R1-R4 have the meanings given in the description, A is CH2, CHOH or CH—(C1-C3-alkyl), B is CH2 or CH—(C1-C3-alkyl), and R5 is an aryl or heteroaryl group, possibly substituted by the substituents listed in the description. These compounds are useful in the upregulation of endothelial nitric oxide synthase (eNOS), and may therefore be useful for the manufacture of medicaments for the treatment of cardiovascular diseases, stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, restenosis, endothelial damage after PTCA, hypertension, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes or diabetes complications, nephropathy or retinopathy, angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, osteoporosis, restricted memory performance, a restricted ability to learn, or for the lowering of cardiovascular risk of postmenopausal women or after intake of contraceptives.

10. 发明专利

AT423777T 未知
公开(公告)号：AT423777T
公开(公告)日：2009-03-15
申请号：AT06754359
申请日：2006-06-14
申请人： SANOFI AVENTIS
发明人： STROBEL HARTMUT , WOHLFART PAULUS , ZOLLER GERHARD , WILL DAVID
IPC分类号： C07D401/06 , A61K31/4439 , A61K31/444 , A61P9/08 , C07D401/08 , C07D401/14 , C07D409/14 , C07D417/06
摘要： The present invention relates to N-alkylamides of the formula I, in which A, Het, X, R 1 , R 2 and R 3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of the formula I, to pharmaceutical compositions comprising them, and to the use of compounds of the formula I for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式